Hence, using potent TNF-α antagonists like ETA could effectively manage MS by preventing its progression via the downregulation of the NF-κB/TNF-α/TGF-β1 signaling pathway and treatment of adipocyte dysfunction, impaired glucose utilization, dyslipidemia, hypertension, and obesity as investigated and confirmed in the current study. Here, TGFB1 is linked to Obesity.